Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ifupinostat hydrochloride (BEBT-908) plus CHOP in previously untreated peripheral T-cell lymphoma
CTR20262046Phase 2Active
- Sponsor
- BeBetter Med
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifupinostat in peripheral T-cell lymphoma (PTCL), sponsored by BeBetter Med. Started May 2026; status: active.
02
Drugs
ifupinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20262046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262046.